Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | ATM | Q13315 | 2/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | CTSB | P07858 | 1/20 | 0.64 |
| ▸ | CTSS | P25774 | 1/20 | 0.64 |
| ▸ | CTSK | P43235 | 1/20 | 0.64 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770866 | 1.00 | ANPEP (0.79) | ANPEPALDH1A1LMNAATMCTSL | |
| SCHEMBL4139513 | 0.88 | ANPEP (0.75) | ANPEPALDH1A1LMNAATMCTSL | |
| SCHEMBL5869443 | 0.87 | ATM (0.75) | ANPEPALDH1A1LMNAATMCTSL | |
| SCHEMBL8248836 | 0.87 | ATM (0.75) | ANPEPALDH1A1LMNAATMCTSL | |
| SCHEMBL5870044 | 0.85 | ANPEP (0.80) | ANPEPALDH1A1LMNAPSMB5MAPT | |
| SCHEMBL8255279 | 0.85 | ANPEP (0.80) | ANPEPALDH1A1LMNAPSMB5MAPT | |
| SCHEMBL13700588 | 0.83 | FOLH1 (0.78) | ALDH1A1LMNA | |
| SCHEMBL28839600 | 0.83 | ALDH1A1 (0.65) | ANPEPALDH1A1LMNAATMMAPT | |
| SCHEMBL8022139 | 0.83 | ALDH1A1 (0.83) | ANPEPALDH1A1LMNAATMPSMB5 | |
| SCHEMBL2563448 | 0.83 | ALDH1A1 (0.83) | ANPEPALDH1A1LMNAATMPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | claimed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-5246960-A | Used to treat obesity, hyperlipaemia, atherosclerosis and arteriosclerosis | HOFFMANN-LA ROCHE INC. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5175186-A | Inhibits pancreas lepase and useful agent in treatment of obesity, hyperlipemia, atherosclerosis and arteriosclerosis | HOFFMANN-LA ROCHE INC. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0185359-B1 | OXETANONE | F. HOFFMANN-LA ROCHE AG (CH) | 1991-12-04 | — | — | EP | disclosed |
| US-4931463-A | PANCREAS LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1990-06-05 | — | — | US | disclosed |
| EP-0185359-A2 | Oxetanone | F. HOFFMANN-LA ROCHE AG (CH) | 1986-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | ANPEP 78/4885ALDH1A1 3651/4885LMNA 2800/4885 |
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | ANPEP 3/4885ALDH1A1 1483/4885LMNA 3319/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | ANPEP 223/4885ALDH1A1 3117/4885LMNA 3527/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | ANPEP 78/4885ALDH1A1 3651/4885LMNA 2800/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | ANPEP 78/4885ALDH1A1 3651/4885LMNA 2800/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | ANPEP 78/4885ALDH1A1 3651/4885LMNA 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.